miR-539 Targeting SNAI2 Regulates MMP9 Signaling Pathway and Affects Blood-Brain Barrier Permeability in Cerebrovascular Occlusive Diseases: A Study Based on Head and Neck Ultrasound and CTA

<div>The expression level of miR-539 in peripheral blood of patients with cerebrovascular occlusive disease decreased significantly. (a) Comparison of miR-539 expression level in peripheral blood between the healthy control group (<i>n</i> = 48) and patients with cerebrovascular occlusive disease (<i>n</i> = 48). (b) CTA examination results of patients with left common carotid artery (left) and right common carotid artery (right) occlusion. (c) Ultrasound hemodynamics of head and neck in patients with left common carotid artery (left) and right common carotid artery (right) occlusion. (d) miR-539 expression level in peripheral blood of patients with unchanged blood-brain barrier permeability (<i>n</i> = 27) and elevated blood-brain barrier permeability (<i>n</i> = 21).</div>

Journal of Healthcare Engineering

fig1

Figure 1

Figure 1: miR-539 Targeting SNAI2 Regulates MMP9 Signaling Pathway and Affects Blood-Brain Barrier Permeability in Cerebrovascular Occlusive Diseases: A Study Based on Head and Neck Ultrasound and CTA 

Figure 1 | miR-539 Targeting SNAI2 Regulates MMP9 Signaling Pathway and Affects Blood-Brain Barrier Permeability in Cerebrovascular Occlusive Diseases: A Study Based on Head and Neck Ultrasound and CTA 